Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

NCT03433469 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Stage I Non-Small Cell Lung Cancer
Stage IA Non-Small Cell Lung Cancer
Stage IB Non-Small Cell Lung Cancer
Stage II Non-Small Cell Lung Cancer
Stage IIA Non-Small Cell Lung Cancer
Stage IIB Non-Small Cell Lung Cancer
Stage IIIA Non-Small Cell Lung Cancer

Interventions

DRUG: Osimertinib
PROCEDURE: Therapeutic Conventional Surgery

Sponsor

University of California, San Francisco

Collaborators

AstraZeneca